Lilly Oncology chief resigns

pharmafile | January 27, 2011 | News story | Research and Development, Sales and Marketing Eli Lilly, John Johnson, Lilly Oncology, appointment, lilly, research and development, sales and marketing 

Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced he would be stepping down.

Johnson was brought in as president of Lilly Oncology after the company’s 2008 acquisition of ImClone Systems, where he served as chief executive.

“Given his previous post at ImClone, John has played a key role leading the integration efforts since Lilly’s acquisition,” said Lilly chairman, president and chief executive John Lechleiter.

“He has always been a champion of serving patients and has guided the Lilly Oncology pipeline to an all-time high – one of the largest clinical-stage pipelines of potential cancer medicines in the industry.”

Johnson’s resignation is effective from tomorrow and Lilly said a successor would be announced in the coming weeks.

Dominic Tyer

Related Content


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content